| DC47344 |
SARS-CoV-2-IN-8
|
SARS-CoV-2-IN-8 is a SARS-CoV-2 main protease inhibitor with an IC50 value of 0.75 μM. |
| DC47343 |
XR8-69
|
XR8-69 is a SARS-CoV-2 PLpro inhibitor that shows low micromolar antiviral potency in SARS-CoV-2-infected human cells. |
| DC47342 |
SARS-CoV-2-IN-6
|
SARS-CoV-2-IN-6 is a SARS-CoV-2 3CLpro inhibitor that shows the most potent enzyme inhibitory IC50 value of 73 nM. |
| DC47341 |
Cichoriin
|
Cichoriin is an active compounds against SARS-CoV-2, and may be a potential candidate in treating severe COVID-19. |
| DC47340 |
SARS-CoV-2-IN-7
|
SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC50 value (844 nM) in SARS-CoV-2-infected Vero E6 cells. |
| DC47339 |
NK007
|
NK007 is a novel anti-SARS-CoV-2 agent with an EC50 value of 30 nM. |
| DC47338 |
SARS-CoV-2-IN-9
|
SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease. |
| DC46821 |
HeE1-2Tyr
|
HeE1-2Tyr, a pyridobenzothiazole compound, is a flavivirus RNA dependent RNA polymerases (RdRp) inhibitor. HeE1-2Tyr significantly inhibits West Nile, Dengue and SARS-CoV-2 RdRps (IC50 of 27.6 µM) activity in vitro. |
| DC46820 |
Lufotrelvir
|
Lufotrelvir (PF-07304814), a phosphate prodrug of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle. |
| DC46819 |
RdRP-IN-2
|
RdRP-IN-2 is a RNA dependent RNA polymerase (RdRp) inhibitor. RdRP-IN-2 significantly inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 µM.RdRP-IN-2 also inhibits Feline coronavirus (FIPV) replication. |
